Mobile

A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physic...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-014605-14

A Phase 4, 8-Week, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily in Outpatients with Major Depressive Disorder and Associated Painful Physical Symptoms

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to test the hypothesis that duloxetine given 60 mg (30 mg for first week) once daily (QD), orally, for 8 weeks is superior to placebo QD, orally, for 8 weeks in the treatment of adult outpatients with MDD and associated painful physical symptoms. The primary objective will be evaluated from 2 perspectives: the reduction of pain severity and the improvement in depressive symptoms.

Critère d'inclusion

  • Major Depressive Disorder

Liens